Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide, deteriorating approximately 1000,000 lives. Annually rising HCC to the third most common cause of cancer mortality. Liver cancer varies geographically depending on multimodality treatments available for this heterogeneous malignancy. Conglomeration of treatments has been exercised to manage this type of cancer across distinct geographic regions. Unprecedented rise of scientific knowledge mining from the published literature is a boon to develop novel treatment modalities. We aim to focus such pharmacological aspects in HCC treatment that could effectively display the improved therapies. Extrapolating the details of liver cancer (classification, diagnosis, adequate treatments, therapeutic engineering involved in the therapy, causes, epidemiology, and survival ratio) and the result obtained through this research could be a magnificent approach in the advancement of drug delivery systems that could assist in clinical trials and further betterment of survival rate and improved therapy from this deadly cancer.
Part of the book: Liver Pathology
Bangham was first to develop these spherical-shaped nano-vesicles called liposomes in the early 1960s. Today, liposomes have emerged as crucial tools for bettering the delivery of drugs that majorly includes-antifungal drug, peptide hormones, enzymes, vaccines antimicrobial agents, drugs against cancer, and genetic materials. Following the different manufacturing practices and versatile properties liposomes can be categorized in various parameters of size, charge, poly-dispersity index, encapsulation efficiency, solubility properties, and lamellarity. Alteration in such parameters elevates the loading and bioavailability of a drug by giving more clear target specification, desired or controlled release. This bibliographic chapter provides a comprehensive overview of methods for the preparation of liposomes with other perspectives that majorly includes—physio-chemical characteristics, dosage regimen, advantages over other delivery systems, approved liposomal based drugs and other ongoing drugs in clinical trials. It will help researchers to breakthrough more structurally successful delivery vehicles depending upon their various physic-chemical properties.
Part of the book: Molecular Pharmacology